Eisai Clinical Trials
Study Overview
E7080
lenvatinib
NCT03477175, 2017-003668-11
Aug 2018 - Dec 2023
Solid Tumors
1. Number of participants with any treatment-emergent (TE) serious adverse event (SAE) [Time Frame: Up to 28 days after the last dose of study drugs or 5 × half-life of study drugs, whichever is longer (up to 10 years)]
2. Number of participants with any non-serious TE adverse event (TEAE) [Time Frame: Up to 28 days after the last dose of study drugs or 5 × half-life of study drugs, whichever is longer (up to 10 years)]
2. Number of participants with any non-serious TE adverse event (TEAE) [Time Frame: Up to 28 days after the last dose of study drugs or 5 × half-life of study drugs, whichever is longer (up to 10 years)]
-
Males and females 18 Years and older (Adult, Older Adult)
-
Completed -
Phase 1 / 2
Australia, Belgium, China, Germany, Italy, Korea, Republic of, Netherlands, Poland, Romania, Thailand, United States See moreData Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
CSDR Sharing is not available for this study.
CSDR Availability Clinical Trial Data Redacted documents may be available upon request for this study.
Document type Availability Protocol SAP Sample CRF Full CSR